Perrigo announced that the FDA has approved the abbreviated New Drug Application for its over-the-counter diclofenac sodium topical gel 1% for the temporary relief of arthritis pain in the hand, wrist, elbow, foot, ankle or knee in adults ≥18 years old.
The FDA Advil Dual Action with Acetaminophen for the temporary relief of minor aches and pains due to arthritis and more.
Investigators explored concerns with regard to opioid prescribing in compliance with new regulations in a commentary piece.
Diclofenac sodium topical gel and olopatadine HCl ophthalmic drops will soon be available over-the-counter (OTC) after the the Food and Drug Administration (FDA) switched the status of these products from prescription to nonprescription.
The over-the-counter (OTC), drug-free medical device, ActiPatch®, has obtained a new 510(k) clearance from the Food and Drug Administration (FDA) for the adjunctive treatment of musculoskeletal pain.
In an effort to further address the current opioid crisis, the FDA contracted the NASEM to examine existing opioid prescribing guidelines and to help outline the type of research needed to fill the gaps in evidence.
Fidia Pharma USA has announced the launch of Triluron (sodium hyaluronate), a hyaluronic acid (HA) based intra-articular viscosupplement.
Data from a study investigating the efficacy and safety of 6-week low-dose prednisolone in patients with painful hand osteoarthritis were presented at the 2019 ACR Annual Meeting.
Patients on long-term opioid treatment for chronic pain reported experiencing negative physical side effects, emotional distress, and degraded relationships with their primary care provider.
Doctors should be more cautious when taking chronic pain patients off opioid painkillers.
